OPKO Health (NASDAQ: OPK) reported Q3 EPS of ($0.08), $0.03 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $263.5 million versus the consensus estimate of $319.43 million.

• RAYALDEE total prescriptions increased 66% in Q3 2017 compared with Q2 2017
• 4Kscore utilization increased 19% in Q3 2017 compared with Q3 2016
• 4Kscore TV ads in the Northeast to begin November 21
• Submitted a Premarket Approval (PMA) application with FDA for Claros point-of-care (POC) prostate specific antigen (PSA) test
• Exclusive agreement with Japan Tobacco to develop and commercialize RAYALDEE in Japan
• Enrollment for global pediatric Phase 3 hGH-CTP clinical trial continues; Japanese pediatric registration trial underway
• Intravenous VARUBI® approved by US FDA with launch expected November 2017; addresses 90% of the market for chemotherapy induced nausea and vomiting (CINV); OPKO to receive double digit royalties
• Plans to initiate four Phase 2 programs in late 2017 or early 2018
• Consolidated revenue for the three months ending September 30, 2017 was $263.5 million compared to $298.0 million for the comparable 2016 period
• Net loss for the three months ending September 30, 2017, was $46.4 million compared to net loss of $15.0 million for the comparable 2016 period as OPKO invested heavily this quarter in future growth

For earnings history and earnings-related data on OPKO Health (OPK) click here.